Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2812-2823

  Tsui, Ke Hung ^a,b   Chung, Li Chuan ^b   Feng, Tsui Hsia ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

androgen receptor; BTG2; luteolin; maspin; NDRG1; PDEF; prostate; PSA

Indexed keywords

LUTEOLIN; THYMIDINE; TRITIUM;

ANDROGEN RECEPTOR GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL TRANSLOCATION GENE 2; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MASPIN GENE; N MYC DOWNSTREAM REGULATED GENE 1; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROSTATE DERIVED ETS FACTOR GENE; PSA GENE; TRANSCRIPTION REGULATION; UPREGULATION;

APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUTEOLIN; MALE; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, ANDROGEN; SERPINS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84859905254     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26284     Document Type: Article

References (49)

1. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, et al. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000; 275: 1216-25. (Pubitemid 30051174)
2. Thelen P, Jarry H, Ringert RH, Wuttke W,. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med 2004; 70: 397-400. (Pubitemid 38716470)
3. Thelen P, Scharf JG, Burfeind P, Hemmerlein B, Wuttke W, Spengler B, Christoffel V, Ringert RH, Seidlova-Wuttke D,. Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer. Carcinogenesis 2005; 26: 1360-7. (Pubitemid 41417878)
4. Juang HH, Lin YF, Chang PL, Tsui KH,. Cardiac glycosides reduce prostate specific antigen expression by downregulation of prostate-derived ets factor. J Urol 2010; 84: 2158-64.
5. Tsui KH, Feng TH, Lin CM, Chang PL, Juang HH,. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl 2008; 29: 661-8.
6. Cho JY, Lee M, Ahn JM, Park ES, Cho JH, Lee SJ, Kim BG, Heo SH, Park HJ, Zerbini LF, Hwang D, Libermann TA,. Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex. J Proteome Res 2009; 8: 1327-37.
7. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK,. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 2008; 19: 3745-57.
8. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA,. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67: 4219-26. (Pubitemid 46815068)
9. Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I, Starace G, Caruso M, Tirone F,. Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 2000; 20: 1797-1815. (Pubitemid 30100197)
10. Walden PD, Lefkowitz GK, Ficazzola M, Gitlin J, Lepor H,. Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. Exp Cell Res 1998; 245: 19-26. (Pubitemid 28551051)
11. Tsui KH, Hsieh WC, Lin MH, Chang PL, Juang HH,. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2. Prostate 2008; 68: 610-9.
12. Amin R, Kucuk O, Khuri FR, Shin DM,. Perspective for cancer prevention with natural compound. J Clin Oncol 2009; 27: 2712-25.
13. Shimoi K, Saka N, Kaji K, Nozawa R, Kinae N,. Metabolic fate of luteolin and its functional activity at focal site. Biofactors 2000; 12: 181-6. (Pubitemid 32107405)
14. Coleman DT, Bigelow R, Cardelli JA,. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 2009; 8: 214-24.
15. Chiu FL, Lin JK,. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate 2008; 68: 61-71.
16. Fang J, Zhou Q, Shi X-L, Jiang B-H,. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis 2007; 28: 713-23. (Pubitemid 46523369)
17. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV,. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005; 280: 5636-45. (Pubitemid 40280043)
18. Kobayashi T, Nakata T, Kuzumaki T,. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett 2002; 176: 17-23. (Pubitemid 34085065)
19. Tsui KH, Chang PL, Juang HH,. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. Int J Cancer 2006; 118: 609-15.
20. Tsui KH, Chang PL, Lin HT, Juang HH,. Down-regualtion of the prostate specific antigen promoter by p53 in human prostae cancer cells. J Urol 2004; 172: 2035-9.
21. Tsui KH, Wu L, Chang PL, Hsieh ML, Juang HH,. Identifying the combination of the transcriptional regulatory sequences on prostate specific antigen and human glandular kallikrein genes. J Urol 2004; 172: 2029-34. (Pubitemid 39363122)
22. Tsui KH, Chang PL, Feng TH, Chung LC, Shu SY, Juang HH,. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. AntiCancer Res 2008; 28: 1977-84.
23. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK,. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003; 63: 4626-31. (Pubitemid 36951040)
24. Edwards J, Bartlett JMS,. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 2005; 95: 1327-35. (Pubitemid 40799455)
25. Thelen P, Peter T, Hunermund A, Kaulfuss S, Seidlova-Wuttke D, Wuttke W, Ringert RH, Seseke F,. Phytoestrogens from Belamcanda chinensis regulates the expression of steroid receptors and related cofactors in LNCaP prostate cancer cells. BJU Int 2007; 100: 199-203. (Pubitemid 46878569)
26. Tirone F,. The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 2001; 187: 155-65. (Pubitemid 32270074)
27. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD,. Antiproliferative B cell translocation gene 2 protein is down regulated posttranscriptionally as an early event in prostate carcinogenesis. Carcinogenesis 2001; 22: 1271-9. (Pubitemid 32737344)
28. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF,. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002; 277: 14877-83. (Pubitemid 34952561)
29. Sasajima H, Nakagawa K, Yokosawa H,. Antiproliferative proteins of the BTG/Tob family are degraded by the ubuquitin-proteasome system. Eur J Biochem 2002; 269: 3596-604. (Pubitemid 34989004)
30. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M, Sata M,. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 2006; 66: 4826-34.
31. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS,. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 2008; 87: 401-6.
32. Lim Y, Jeong Y, Tyner AL, Park JH,. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 2007; 292: G66-75. (Pubitemid 46090252)
33. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, Nozaki M,. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000; 60: 1348-52. (Pubitemid 30152005)
34. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK,. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer 2010; 9: 148.
35. Schaefer JS, Sabherwal Y, Shi HY, Sriraman V, Richards J, Minella A, Turner DP, Watson DK, Zhang M,. Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression. J Biol Chem 2010; 285: 11258-69.
36. Schmidt U, Fuessel S, Koch R, Baretton GB, Lohse A, Tomasetti S, Unversucht S, Froehner M, Wirth MP, Meye A,. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006; 66: 1521-34. (Pubitemid 44465817)
37. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J,. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 2007; 8: 1628-38. (Pubitemid 47589085)
38. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F,. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102: 19-30.
39. Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F,. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 2008; 123: 1376-84.
40. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK,. Prostate-derived Ets factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007; 67: 1618-25. (Pubitemid 46383387)
41. Findlay VJ, Turner DP, Moussa O, Watson DK,. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res 2008; 68: 8499-506.
42. Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Ceradts J,. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis. Cancer Epidemiol Biomarkers Prev 2009; 18: 1899-903.
43. Li X, Chen D, Ying S, Meng Y, Yang H, Landis-Piwowar KR, Li Y, Sarkar FH, Reddy GP, Dou QP, Sheng S,. Maspin augments proteasome inhibitor-induced apoptosis in prostate cancer cells. J Cell Physiol 2007; 212: 298-306. (Pubitemid 47025618)
44. Chen ML, Biliran HR Jr, Bhagat S, Menckett J, Abrams J, Fridman R, Zachareas M, Sheng S,. Maspin expression inhibits oesteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. PNAS 2003; 100: 7847-52. (Pubitemid 36760058)
45. Watanabe M, Nasu Y, Kashiwakura Y, Kusumi N, Tamayose K, Nagai A, Sasano T, Shimasa T, Daida H, Kumon H,. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther 2005; 16: 699-710. (Pubitemid 40864270)
46. Hall DC, Johnson-Pais TL, Grubbs B, Bernal R, Leach RJ, Padalecki SS,. Maspin reduces prostate cancer metastasis to bone. Urol Oncol 2008; 26: 652-8.
47. Tu LC, Yan X, Hood L, Lin B,. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 2007; 6: 575-88. (Pubitemid 46630091)
48. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033-41. (Pubitemid 46910214)
49. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M, Watabe K,. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res 2003; 63: 1731-6. (Pubitemid 36460828)